Veliparib
- Generic Name
- Veliparib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C13H16N4O
- CAS Number
- 912444-00-9
- Unique Ingredient Identifier
- 01O4K0631N
- Indication
与化疗药物紫杉醇和卡铂联合用于治疗乳腺癌。
- Associated Conditions
- -
- Associated Therapies
- -
Veliparib and Floxuridine in Treating Patients With Metastatic Epithelial Ovarian, Primary Peritoneal Cavity, or Fallopian Tube Cancer
- First Posted Date
- 2012-12-13
- Last Posted Date
- 2020-07-02
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 29
- Registration Number
- NCT01749397
- Locations
- 🇺🇸
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
🇺🇸Mayo Clinic in Rochester, Rochester, Minnesota, United States
🇺🇸Siteman Cancer Center at Washington University, Saint Louis, Missouri, United States
Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IV Head and Neck Cancer
- Conditions
- Interventions
- First Posted Date
- 2012-10-22
- Last Posted Date
- 2023-06-07
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 24
- Registration Number
- NCT01711541
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
🇺🇸NorthShore University HealthSystem-Evanston Hospital, Evanston, Illinois, United States
Veliparib and Topotecan for Relapsed Ovarian Cancer With Negative or Unknown BRCA Status
- First Posted Date
- 2012-09-24
- Last Posted Date
- 2015-06-10
- Lead Sponsor
- Vejle Hospital
- Target Recruit Count
- 22
- Registration Number
- NCT01690598
- Locations
- 🇩🇰
Department of Oncology, Vejle Hospital, Vejle, Denmark
Comparison of Veliparib and Whole Brain Radiation Therapy (WBRT) Versus Placebo and WBRT in Adults With Brain Metastases From Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2012-08-06
- Last Posted Date
- 2018-06-06
- Lead Sponsor
- AbbVie (prior sponsor, Abbott)
- Target Recruit Count
- 307
- Registration Number
- NCT01657799
Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer
- First Posted Date
- 2012-07-17
- Last Posted Date
- 2023-05-06
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 156
- Registration Number
- NCT01642251
- Locations
- 🇺🇸
Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸Greenville Health System Cancer Institute-Easley, Easley, South Carolina, United States
🇺🇸Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
Temozolomide With or Without Veliparib in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2012-07-11
- Last Posted Date
- 2019-11-19
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 97
- Registration Number
- NCT01638546
- Locations
- 🇺🇸
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
🇺🇸M D Anderson Cancer Center, Houston, Texas, United States
🇺🇸Virginia Commonwealth University/Massey Cancer Center, Richmond, Virginia, United States
Pre-Operative Radiation and Veliparib for Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2012-06-13
- Last Posted Date
- 2024-05-22
- Lead Sponsor
- Richard Zellars
- Target Recruit Count
- 19
- Registration Number
- NCT01618357
- Locations
- 🇺🇸
I U Health West, Avon, Indiana, United States
🇺🇸Indiana University Health Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States
🇺🇸Indiana University Health Methodist Hospital, Indianapolis, Indiana, United States
A Clinical Study Conducted in Multiple Centers Evaluating Escalating Doses of Veliparib in Combination With Capecitabine and Radiation in Patients With Locally Advanced Rectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2012-05-02
- Last Posted Date
- 2017-11-20
- Lead Sponsor
- AbbVie (prior sponsor, Abbott)
- Target Recruit Count
- 32
- Registration Number
- NCT01589419
- Locations
- 🇺🇸
Site Reference ID/Investigator# 99095, Scottsdale, Arizona, United States
🇺🇸Site Reference ID/Investigator# 68045, Durham, North Carolina, United States
🇦🇺Site Reference ID/Investigator# 67882, East Melbourne, Australia
Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2012-04-26
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 107
- Registration Number
- NCT01585805
- Locations
- 🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
🇺🇸Ingalls Memorial Hospital, Harvey, Illinois, United States
🇺🇸University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Castration-Resistant Prostate Cancer
- First Posted Date
- 2012-04-12
- Last Posted Date
- 2020-11-12
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 159
- Registration Number
- NCT01576172
- Locations
- 🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
🇺🇸City of Hope South Pasadena, South Pasadena, California, United States
🇺🇸NorthShore University HealthSystem-Evanston Hospital, Evanston, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.